Teladoc Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
$2.56B revenue 2024; Q2 2025 $631.9M (-1.6% YoY); 101-103M projected US members 2025; telehealth market leader; telehealth market $123.26B 2024 to $455.27B 2030; 46.58% North America share
About
Teladoc Health is the world's largest telehealth company, founded in 2002 and headquartered in Purchase, New York, that pioneered on-demand virtual healthcare delivery in the United States. The company was founded on the premise that patients should be able to access physicians anytime and anywhere without traveling to a physical office — a model that took over a decade to gain mainstream acceptance before becoming a necessity during the COVID-19 pandemic. Teladoc's mission is to provide whole-person virtual care that addresses physical health, mental health, and chronic condition management through an integrated digital platform.\n\nTeladoc's platform encompasses general medical, dermatology, nutrition, and specialty care through its core telehealth offering; mental health and therapy through BetterHelp, the world's largest online therapy platform; virtual primary care and chronic condition management through Teladoc Primary360; and complex care navigation through its integrated whole-person health approach. The company serves employers, health plans, hospitals, and health systems, delivering virtual care to members across the US and internationally. BetterHelp has become a significant consumer-facing revenue driver, connecting individuals directly with licensed therapists without employer or insurance intermediaries.\n\nTeladoc reported $2.56 billion in revenue for 2024 and projects 101 to 103 million US members in 2025. The company trades on the NYSE under TDOC and holds a substantial lead in telehealth market share through its scale, multi-specialty breadth, and direct-to-consumer mental health reach via BetterHelp. Despite post-pandemic normalization and the $13.7 billion Livongo write-down in 2022, Teladoc remains the largest and most diversified virtual care platform, with continued investment in AI-powered clinical decision support and chronic disease management to drive the next phase of growth.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.